发明授权
- 专利标题: Mycobacterial inhibitors
- 专利标题(中): 分枝杆菌抑制剂
-
申请号: US11007026申请日: 2004-12-08
-
公开(公告)号: US07498343B2公开(公告)日: 2009-03-03
- 发明人: Jozef Frans Elisabetha Van Gestel , Jérôme Emile Georges Guillemont , Marc Gaston Venet , Hervé Jean Joseph Poignet , Laurence Françoise Bernadette Decrane , Daniel F. J. Vernier , Frank Christopher Odds
- 申请人: Jozef Frans Elisabetha Van Gestel , Jérôme Emile Georges Guillemont , Marc Gaston Venet , Hervé Jean Joseph Poignet , Laurence Françoise Bernadette Decrane , Daniel F. J. Vernier , Frank Christopher Odds
- 申请人地址: BE Beerse
- 专利权人: Janssen Pharmaceutica N.V.
- 当前专利权人: Janssen Pharmaceutica N.V.
- 当前专利权人地址: BE Beerse
- 代理商 John Harbour
- 主分类号: A61K31/44
- IPC分类号: A61K31/44 ; C07D215/38
摘要:
The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R1 is bromo, p=1, R2 is alkyloxy, R3 is optionally substituted naphthyl or phenyl, q=1, R4 and R5 each independently are hydrogen, methyl or ethyl, R6 is hydrogen, r is equal to 0 or 1 and R7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
公开/授权文献
- US20050148581A1 Novel mycobacterial inhibitors 公开/授权日:2005-07-07